Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
暂无分享,去创建一个
A. Iavarone | P. Zoppoli | Y. Marie | M. Sanson | S. Yip | A. Idbaih | G. Finocchiaro | J. Tabernero | J. Soria | M. Eoli | A. Kamoun | K. Mokhtari | A. Lasorella | V. Frattini | J. Savatovsky | C. Houillier | K. Petrecca | M. Labussière | B. Boisselier | H. Belaid | F. Luo | R. Paterra | M. Touat | M. Giry | A. D. Di Stefano | J. Chan | A. Bruno | A. Fucci
[1] Amanda C. Schierz,et al. canSAR: an updated cancer research and drug discovery knowledgebase , 2015, Nucleic Acids Res..
[2] Y. Marie,et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.
[3] P. Jänne,et al. Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma , 2014, Clinical Cancer Research.
[4] Y. Marie,et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.
[5] Nicolas Stransky,et al. The landscape of kinase fusions in cancer , 2014, Nature Communications.
[6] M. Gilbert,et al. Advances in treating glioblastoma , 2014, F1000prime reports.
[7] Lei Wang,et al. FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.
[8] J. Tabernero,et al. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. , 2014 .
[9] Steven J. M. Jones,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[10] The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[11] L. Deangelis,et al. Glioblastoma and other malignant gliomas: a clinical review. , 2013, JAMA.
[12] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[13] R. Bernards,et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing , 2013, The Journal of pathology.
[14] Nickolay A. Khazanov,et al. Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.
[15] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[16] V. P. Collins,et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.
[17] M. Nykter,et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. , 2013, The Journal of clinical investigation.
[18] M. Knowles,et al. Oncogenic FGFR3 gene fusions in bladder cancer , 2012, Human molecular genetics.
[19] Mary Goldman,et al. The UCSC Cancer Genomics Browser: update 2015 , 2014, Nucleic Acids Res..
[20] M. Sanson,et al. Molecular analysis of diffuse intrinsic brainstem gliomas in adults , 2013, Journal of Neuro-Oncology.
[21] D. Brat,et al. Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.
[22] M. Sanson,et al. Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients , 2012, Cancer.
[23] K. Hoang-Xuan,et al. Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas , 2012, Clinical Cancer Research.
[24] J. Demoulin,et al. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies , 2012, Journal of cellular and molecular medicine.
[25] H. Fine,et al. Many tumors in one: a daunting therapeutic prospect. , 2011, Cancer cell.
[26] Rebecca A Betensky,et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.
[27] C. Murray,et al. Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models , 2011, Molecular Cancer Therapeutics.
[28] Mary Goldman,et al. The UCSC cancer genomics browser: update 2011 , 2010, Nucleic Acids Res..
[29] Yoshitaka Narita,et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.
[30] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Gilbert S Omenn,et al. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer , 2009, Nature Biotechnology.
[32] K. Hoang-Xuan,et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] K. Hoang-Xuan,et al. Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma , 2009, Neuropathology and applied neurobiology.
[34] Emmanuel Barillot,et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas , 2007, International journal of cancer.
[35] B. Johansson,et al. The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.
[36] K. Hoang-Xuan,et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas , 2006, Cancer.
[37] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[38] B. Wullich,et al. Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. , 2005, Clinical chemistry.
[39] M. Wigler,et al. Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.
[40] Glyn Johnson,et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. , 2004, AJNR. American journal of neuroradiology.
[41] K. Hoang-Xuan,et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression , 2001, Neurology.